INTRODUCTION
Mitral regurgitation (MR) is a common heart valve disease, in which the
mitral valve fails to close during the left ventricular systole and
causes blood to flow from the left ventricle to the left atrium,
including primary (degenerative) MR and secondary (functional)
MR.[1] With the gradual aging of the global
population, the number of MR patients has shown an upward trend year by
year and the annual mortality rate was as high as
34%.[2] The treatment methods of MR mainly
include drug therapy, surgery and percutaneous interventional therapy.
Drug therapy can only improve the symptoms of the patient, but cannot
prolong the survival time; the surgical operation includes mainly valve
repair and valve replacement, which is considered to be the standard
treatment for MR. Percutaneous intervention technology has become a
supplementary treatment option for high-risk MR patients who cannot
withstand the blow of surgery. [3] After 30 years
of development, Minimally invasive cardiac surgery (MICS) technology
reduces the trauma caused by the operation itself in the case of
providing the same curative effect as the C-MVS operation. In recent
years, there have been studies that directly compared different
minimally invasive options, such as R-MVS, 3D-MVS, T-MVS, M-MVS, C-MVS,
etc., but lack of network meta-analysis research. This study has been
used to systematically evaluates the respective advantages and mid-term
efficacy of different surgical procedures, discuss the best minimally
invasive MV surgery and provide clinical reference for the majority of
cardiac surgery colleagues.
MATERIALS AND METHODS
Patient and public involvement No patients were involved.